# ABC294640 in Treating Patients With Advanced Solid Tumors

> **NCT01488513** · PHASE1 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 22 (actual)

## Conditions studied

- Pancreatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sphingosine kinase-2 inhibitor ABC294640

## Key facts

- **NCT ID:** NCT01488513
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-08
- **Final completion:** 2015-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-01-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01488513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01488513, "ABC294640 in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01488513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*